albutrepenonacog alfa: clinical use

Prescribing considerations

• Initiate and supervise treatment through clinicians experienced in haemophilia B.
• Record product name and batch number for biological-medicine traceability.
• Initial administration should be considered under medical observation because factor IX products can cause acute hypersensitivity.
• Assess thrombotic risk in liver disease, perioperative care, newborn infants and patients at risk of thrombosis or disseminated intravascular coagulation.
• Consider infection, bacteraemia and catheter-site thrombosis risks if central venous access is required.
• Safety and efficacy for immune-tolerance induction have not been established.

Contraindications and cautions

• Hypersensitivity to albutrepenonacog alfa or any excipient
• Known allergic reaction to hamster protein

Monitoring

• Assess clinical response and plasma factor IX activity to individualise treatment.
• Monitor for neutralising factor IX inhibitors, particularly with inadequate haemostatic response or hypersensitivity.
• One-stage clotting results depend on the reagent and reference standard; kaolin-based or Actin FS reagents may underestimate activity.
• Use clinical and laboratory surveillance for thrombotic or consumptive coagulopathy in at-risk patients.

Clinical pharmacology

A recombinant factor IX–albumin fusion protein. Albumin fusion prolongs systemic exposure; activation cleaves the albumin component and releases active factor IX into the coagulation pathway.

Formulation and product differences

• Supplied as powder with water for injections and an administration kit.
• Reconstituted concentration and solvent volume vary between vial presentations.
• Do not dilute or mix with other medicines; use the supplied injection equipment because adsorption to some equipment may reduce delivered factor IX.
• The prepared solution should preferably be used immediately and must be visually inspected before administration.

Injection

Route: Parenteral

Strengths: 3500 units